Embecta Corp. (NASDAQ:EMBC) Stock Now Rated “Reduce” by Sell-Side Analysts

25 Sep 2026, 07:29 by Danessa Lincoln · The Markets Daily

Embecta Corp. (NASDAQ:EMBC – Get Free Report) has been assigned an average rating of “Reduce” from the five ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating and three have given a hold rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $11.00.

A number of equities analysts have weighed in on the stock. Zacks Research raised shares of Embecta from a “strong sell” rating to a “hold” rating in a research report on Friday, July 17th. Weiss Ratings lowered Embecta from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, August 3rd.

Get Our Latest Report on Embecta

Embecta Stock Up 0.7%

NASDAQ EMBC opened at $5.62 on Friday. Embecta has a fifty-two week low of $2.77 and a fifty-two week high of $14.91. The business has a 50 day moving average price of $4.70 and a two-hundred day moving average price of $5.36. The stock has a market cap of $318.43 million, a PE ratio of 3.80 and a beta of 0.86.

Embecta (NASDAQ:EMBC – Get Free Report) last posted its quarterly earnings data on Friday, August 7th. The company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.29. The company had revenue of $271.70 million for the quarter, compared to analyst estimates of $254.53 million. Embecta had a net margin of 8.59% and a negative return on equity of 19.25%. The business’s quarterly revenue was down 8.1% on a year-over-year basis. During the same quarter last year, the firm posted $1.12 earnings per share. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. Sell-side analysts anticipate that Embecta will post 1.84 EPS for the current fiscal year.

Embecta Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 15th. Shareholders of record on Thursday, August 27th were paid a dividend of $0.01 per share. This represents a $0.04 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date was Thursday, August 27th. Embecta’s dividend payout ratio (DPR) is 2.70%.

Insiders Place Their Bets

In other news, Director Milton Mayo Morris sold 6,293 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $5.88, for a total transaction of $37,002.84. Following the completion of the transaction, the director directly owned 53,828 shares in the company, valued at approximately $316,508.64. This represents a 10.47% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Jeffrey Z. Mann purchased 20,000 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The shares were bought at an average cost of $4.99 per share, with a total value of $99,800.00. Following the transaction, the insider directly owned 262,915 shares of the company’s stock, valued at approximately $1,311,945.85. This represents a 8.23% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased 70,000 shares of company stock valued at $334,200 over the last 90 days. 1.30% of the stock is owned by company insiders.

Institutional Trading of Embecta

Several institutional investors have recently added to or reduced their stakes in the stock. Isthmus Partners LLC raised its stake in Embecta by 5.5% during the first quarter. Isthmus Partners LLC now owns 146,342 shares of the company’s stock worth $1,294,000 after acquiring an additional 7,613 shares in the last quarter. Intech Investment Management LLC boosted its stake in shares of Embecta by 13.5% in the 4th quarter. Intech Investment Management LLC now owns 63,947 shares of the company’s stock valued at $760,000 after purchasing an additional 7,616 shares in the last quarter. Royce & Associates LP lifted its holdings in Embecta by 30.7% during the 4th quarter. Royce & Associates LP now owns 36,971 shares of the company’s stock valued at $439,000 after purchasing an additional 8,682 shares during the last quarter. State of Wyoming boosted its position in Embecta by 61.5% in the first quarter. State of Wyoming now owns 24,587 shares of the company’s stock valued at $217,000 after buying an additional 9,366 shares in the last quarter. Finally, One Wealth Advisors LLC acquired a new position in Embecta in the second quarter valued at about $33,000. 93.83% of the stock is owned by institutional investors and hedge funds.

Embecta Company Profile

(Get Free Report)

Embecta Corporation (NASDAQ: EMBC) is a global diabetes-care company that develops and manufactures products designed to support insulin delivery and diabetes management. Its portfolio includes pen needles, insulin syringes, safety needles, lancets and other injection-related products used by people with diabetes and healthcare professionals.